Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5916918 | Molecular Immunology | 2013 | 8 Pages |
Abstract
GM-CSF is a well-known haemopoietic growth factor that is used in the clinic to correct neutropaenia, usually as a result of chemotherapy. GM-CSF also has many pro-inflammatory functions and recent data implicates GM-CSF as a key factor in Th17 driven autoimmune inflammatory conditions. In this review we summarize the findings that have led to the development of GM-CSF antagonists for the treatment of autoimmune diseases like rheumatoid arthritis (RA) and discuss some results of recent clinical trials of these agents.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Biology
Authors
Annemarie van Nieuwenhuijze, Marije Koenders, Debbie Roeleveld, Matthew A. Sleeman, Wim van den Berg, Ian P. Wicks,